Skip to main content
. 2023 Jul 12;24(14):11370. doi: 10.3390/ijms241411370

Table 1.

Published studies with available data on molecular therapeutic targets for ACC. ORR: objective response rate, mPFS: median progression-free survival, NR: not reached.

Study Number of Treated Patients Subtype Drug ORR(%) mPFS (mo)
Gilbert et al. [84] 45 Salivary gland carcinoma Paclitaxel 0 4
Pfeffer et al. [85] 10 Adenoid cystic carcinoma Imatinib 0 6
Hotte et al. [86] 15 Adenoid cystic carcinoma Imatinib 0 2.5
Ghosal et al. [87] 28 Adenoid cystic carcinoma Imatinib + Cisplatin 0 15
Wong et al. [88] 40 Adenoid cystic carcinoma Desatinib 2.5 4.8
Chau et al. [89] 13 Adenoid cystic carcinoma Sunitinib 0 7.2
Jakob et al. [90] 19 Adenoid cystic carcinoma Gefitinib 0 4.3
Locati et al. [91] 30 Adenoid cystic + non adenoid cystic carcinoma Cetuximab 0 6
Agulnik et al. [92] 19 Adenoid cystic carcinoma Lapatinib 0 3.5
Dillon et al. [93] 34 Adenoid cystic carcinoma Dovitinib 0 8.2
Locati et al. [94] 26 Adenoid cystic carcinoma Lenvatinib 0 9.1
Tchekmedyian et al. [95] 32 Adenoid cystic carcinoma Lenvatinib 0 17.5
Pfister et al. [96] 32 Adenoid cystic carcinoma Lenvatinib 15.6 17.5
Ho et al. [97] 33 Adenoid cystic carcinoma Axitinib 0 5.7
Ho et al. [98] 38 Adenoid cystic carcinoma Regorafenib NR NR
Thomson et al. [99] 23 Adenoid cystic carcinoma Sorafenib 0 11.3
Guigay et al. [100] 46 Adenoid cystic carcinoma Pazopanib 0 5.9
Even et al. [101] 22 Adenoid cystic carcinoma NOTCH inhibitor crenigacestat (LY3039478) NR 5.3
Ferrarotto et.al. [102] 48 Solid tumors (adenoid cystic carcinoma) Brontictuzumab NR 2
Miranda et al. [103] 41 Solid tumors and hematological malignancies (adenoid cystic carcinoma) CB-103 NR 5
ACCURACY [104] 87 Adenoid cystic carcinoma AL 101 15 NR
Dong-Wan et al. [105] 34 Adenoid cystic carcinoma Everolimus NR 11.2
Fayette et al. NISCAHN. [106] 46 Salivary gland carcinoma Nivolumab 0 4.9
KEYNOTE-028 [107] 26 Salivary gland carcinoma Pembrolizumab 12 4
Mahmood et al. [108] 10 Adenoid cystic carcinoma Pembrolizumab 0 4.5
HHS Vulnerability Disclosure